Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Straynut who wrote (12730)	4/22/2020 6:51:29 PM
From: HardToFind	Respond to of 12871

Still showing slide #1...is there a way to advance to subsequent slides?

To: Straynut who wrote (12730)	4/22/2020 8:01:34 PM
From: HardToFind	Read Replies (1) \| Respond to of 12871

*Diwan's Key Points of the Planet MicroCap Presentation:* A safe Covid-19 vaccine will take extensive testing, and will prevent infection only if given long enough before encountering the virus to develop sufficient antibodies. A vaccine may not be effective if the virus evolves and mutates too quickly. The world needs a broad-spectrum corona-virus treatment, which NNVC intends to provide. NNVC has developed several broad-spectrum corona-virus candidates (originally developed for SARS) that show high effectivity to ACE2 coronavirus SARS samples in cell cultures. NNVC is making 1 Kg batches, which can treat 200-1000 patients, depending on the activity/effectivity level of the drug. They can make one batch every 3-4 weeks for severely at-risk patients. Next step is BioSafety Level 3 or 4 testing with the Covid-19 virus on multiple drug candidates. NNVC is now in contract negotiations for a lab to perform these cell culture tests. NNVC will pick the top 2-3 candidates from these test results. NNVC has found a Covid-19 animal model and intends to do side-by-side safety & toxicology animal studies. This animal model shows no clinical human-like symptoms, but will NNVC will use biometrics (e.g., viral load comparisons, weight loss, etc.) to show animal efficacy. Then, assuming success in animals, they intend to go into human trials with severe and moderately severe patients...pandemic-protocol, not randomized trials.